TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Horizon Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
What was Horizon Therapeutics’s price range in the past 12 months?
Horizon Therapeutics lowest stock price was $66.41 and its highest was $111.70 in the past 12 months.
What is Horizon Therapeutics’s market cap?
Horizon Therapeutics’s market cap is $24.93B.
What is Horizon Therapeutics’s price target?
The average price target for Horizon Therapeutics is $132.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $141.00 ,the lowest forecast is $107.00. The average price target represents 19.60% Increase from the current price of $110.37.
What do analysts say about Horizon Therapeutics?
Horizon Therapeutics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
When is Horizon Therapeutics’s upcoming earnings report date?
Horizon Therapeutics’s upcoming earnings report date is Nov 08, 2021 which is next month.
How were Horizon Therapeutics’s earnings last quarter?
Horizon Therapeutics released its earnings results on Aug 04, 2021. The company reported $0.672 earnings per share for the quarter, missing the consensus estimate of $0.871 by -$0.199.
Is Horizon Therapeutics overvalued?
According to Wall Street analysts Horizon Therapeutics’s price is currently Undervalued.
Does Horizon Therapeutics pay dividends?
Horizon Therapeutics does not currently pay dividends.
What is Horizon Therapeutics’s EPS estimate?
Horizon Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Horizon Therapeutics have?
Horizon Therapeutics has 225,890,000 shares outstanding.
What happened to Horizon Therapeutics’s price movement after its last earnings report?
Horizon Therapeutics reported an EPS of $0.672 in its last earnings report, missing expectations of $0.871. Following the earnings report the stock price went up 6.626%.
Which hedge fund is a major shareholder of Horizon Therapeutics?
Among the largest hedge funds holding Horizon Therapeutics’s share is Paulson & Co Inc. It holds Horizon Therapeutics’s shares valued at 748M.